All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Israel's Protalix BioTherapeutics Q3 revenue rises, driven by higher sales to Chiesi

By Reuters News


Overview

  • Israel biopharma firm's Q3 revenue and net income rose yr/yr

  • Company expects to meet or exceed 2026 revenue guidance

  • Q3 results driven by higher sales to Chiesi, partially offset by lower sales to Fiocruz


Outlook

  • Protalix expects 2026 total revenue of $78 mln to $83 mln

  • Company forecasts 2026 Elfabrio sales, excluding milestones, of $33 mln to $35 mln

  • Protalix anticipates 2026 Elelyso sales of $20 mln to $23 mln


Result Drivers

  • HIGHER SALES TO CHIESI - Co said Q3 revenue growth was primarily driven by increased sales to Chiesi

  • LOWER SALES TO FIOCruz - Q3 sales to Fiocruz (Brazil) declined, which partially offset revenue growth, per co

  • LOWER LICENSE AND R&D REVENUE - Q3 revenue from license and R&D services fell due to fewer services provided to Chiesi


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 EPS

$0.05

Q3 Net Income

$3.96 mln

Q3 Operating Income

$4.05 mln

Q3 Pretax Profit

$4.62 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The stock recently traded at 32 times the next 12-month earnings vs. a P/E of 21 three months ago


Reuters Recommended Reads

  • Nov 9 - Israel's Kamada Q3 revenue up 11%, raises forecast

  • Nov 9 - Israel's Compugen Q3 revenue doubles on Gilead payments; loss narrows

  • Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.